Glenmark launches unique fixed dose combination drug for diabetes
newsdepo.com
The Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter Inhibitor (SGLT2i) â Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibiGlenmark launches unique fixed dose combination drug for diabetes
The Mumbai based drug firm said it has introduced fixed dose combination (FDC) of its novel, patent protected Sodium Glucose Co-Transporter Inhibitor (SGLT2i) â Remogliflozin Etabonate and another widely used DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor) â Vildagliptin, with Metformin. Read more